Ichiyama Satoshi, Suzuki Katsuhiro
Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto-shi, Kyoto 606-8507, Japan.
Kekkaku. 2005 Feb;80(2):95-111.
Clinical bacteriology pertaining to acid-fast bacteria has made marked advances over the past decade, initiated by the development of a DNA probe kit for identification of acid-fast bacteria. Wide-spread use of nucleic acid amplification for rapid detection of tubercle bacillus contributed more greatly than any other factor to such advances in this field. At present, 90% of all kits used for nucleic acid amplification in the world are consumed in Japan. Unfortunately, not a few clinicians in Japan have a false idea that the smear method and nucleic acid amplification are necessary but culture is not. In any event nucleic acid amplification has exerted significant impacts on the routine works at bacteriology laboratories. Among others, collecting bacteria by pretreatment with NALC-NaOH has simplified the introduction of the collective mode smear method and liquid media. Furthermore, as clinicians have become increasingly more experienced with various methods of molecular biology, it now seems possible to apply these techniques for detection of genes encoding drug resistance and for utilization of molecular epidemiology in routine laboratory works. Meanwhile, attempts to diagnose acid-fast bacteriosis by checking blood for antibody have also been made, primarily in Japan. At present, two kits for detecting antibodies to glycolipids (LAM, TDM, etc.) are covered by national health insurance in Japan. We have an impression that in Japan clinicians do not have adequate knowledge and skill to make full use of these new testing methods clinically. We, as the chairmen of this symposium, hope that this symposium will help clinicians increase their skill related to new testing methods, eventually leading to stimulation of advances in clinical practices related to acid-fast bacteria in Japan. 1. Smear microscopy by concentration method and broth culture system: Kazunari TSUYUGUCHI (Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center) Smear microscopy and culture still remain the cornerstone to diagnose tuberculosis. However, the classical methods in Japan using direct microscopy and Ogawa solid media were not sufficient for clinical use. In recent years substantial advance has been made in these fields. Concentration of clinical samples by centrifugation improves the sensitivity of smear microscopy with excellent reproducibility. The Mycobacteria Growth Indicator Tube (MGIT) system using liquid media yields high sensitivity and rapidity. Using these methods, more and more tuberculosis cases would be correctly diagnosed and treated adequately based on drug susceptibility testing. 2. New technologies for anti-tuberculosis drug susceptibility testing: Satoshi MITARAI (Bacteriology Division, Reference Centre for Mycobacterium, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association) Several new technologies have been developed to obtain anti-tuberculosis drug susceptibility testing (AST) results rapidly, utilising liquid culture and molecular technologies. Mycobacterium Growth Indicator Tube (MGIT), as a popular liquid culturing and AST system, was evaluated for its accuracy and usefulness. As for isoniazid, MGIT showed 12.6% of discordant result comparing with standard method. These MGIT resistant and Ogawa susceptible strains had relatively high MICs ranging 0.13 to 2.0 microg/ml. The molecular detection of resistant gene mutation is also a useful method to estimate drug resistance rapidly. The rpoB mutation detection is reliable with high sensitivity and specificity. 3. Nucleic acid amplification and novel diagnostic methods: Shunji TAKAKURA (Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine) Sensitivities of nucleic acid amplification tests (NAATs) for the diagnosis of tuberculosis meet clinical requirement that patients with high-risk of transmission should be identified within a day. Comparison of the performance of various NAATs is difficult because of the difference in sample processing and in samples tested among methods and reports. Considering the limitations of NAATs (low sensitivity compared with culture, inability to differentiate dead bacilli from the living), further advances would be expected when novel technologies could confer additional information, such as drug susceptibility, quantity, viability, and genotype. 4. Serodiagnosis of Mycobacterium avium complex lung disease: Seigo KITADA (Department of Internal Medicine, National Hospital Organization Toneyama National Hospital) Mycobacterium avium complex (MAC) organisms are ubiquitous in environment and a contamination in respiratory tracts is sometimes observed, and that complex the diagnosis. We developed a serodiagnostic method for MAC disease using an enzyme immunoassay with the MAC-specific glycopeptidolipid (GPL) core as antigen. A significant increase in GPL core antibodies was detected in sera of patients with MAC pulmonary diseases compared to patients who were colonized with MAC, patients with M. kansasii disease and tuberculosis and healthy subjects. The serodiagnosis is useful for diagnosis of MAC lung disease. 5. Molecular epidemiologic tools for tuberculosis: IS6110 RFLP, Spoligotyping, and VNTR: Tomoshige MATSUMOTO, Hiromi ANO, Tetsuya TAKASHIMA, Izuo TSUYUGUCHI (Osaka Prefectural Medical Center for Respiratory and Allergic Diseases) We have performed molecular typing on about 1,300 culture positive clinical isolates that made up the majority of tuberculosis strains in part of southeast Osaka since 2001 until now. By spoligotyping, about 75% of entire strains belonged to the Beijing strain. Particular spoligotyping descriptions, which were not described in SpolDBIII, were found in the strains with lower than 6 copies of IS6110 RFLP. We described them as Osaka type. We could also show that direct typing from Tb PCR positive sputum of patients with tuberculosis was possible by VNTR and that VNTR with 16 loci was useful in tuberculosis typing in Osaka.
在过去十年中,由于用于鉴定抗酸菌的DNA探针试剂盒的开发,与抗酸菌相关的临床细菌学取得了显著进展。核酸扩增技术广泛应用于结核杆菌的快速检测,这对该领域的进展贡献最大,超过了其他任何因素。目前,全球90%的核酸扩增试剂盒都在日本使用。不幸的是,日本不少临床医生存在错误观念,认为涂片法和核酸扩增是必要的,但培养并非必需。无论如何,核酸扩增对细菌学实验室的日常工作产生了重大影响。其中,通过NALC-NaOH预处理收集细菌,简化了集落涂片法和液体培养基的应用。此外,随着临床医生对各种分子生物学方法的经验日益丰富,现在似乎有可能将这些技术应用于耐药基因编码的检测以及分子流行病学在常规实验室工作中的应用。与此同时,主要在日本,也有人尝试通过检测血液中的抗体来诊断抗酸菌病。目前,日本有两种检测糖脂(LAM、TDM等)抗体的试剂盒被纳入国家医疗保险范围。我们感觉在日本,临床医生在临床上充分利用这些新检测方法方面缺乏足够的知识和技能。作为本次研讨会的主席,我们希望本次研讨会能帮助临床医生提高与新检测方法相关的技能,最终推动日本与抗酸菌相关临床实践的进步。
涂片显微镜检查和培养仍然是诊断结核病的基石。然而,日本使用直接显微镜检查和小川固体培养基的传统方法在临床应用中并不充分。近年来,这些领域取得了显著进展。通过离心浓缩临床样本提高了涂片显微镜检查的灵敏度,且具有出色的可重复性。使用液体培养基的分枝杆菌生长指示管(MGIT)系统具有高灵敏度和快速性。使用这些方法,越来越多的结核病病例将能够基于药敏试验得到正确诊断和充分治疗。
为了快速获得抗结核药物敏感性检测(AST)结果,利用液体培养和分子技术开发了几种新技术。分枝杆菌生长指示管(MGIT)作为一种常用的液体培养和AST系统,对其准确性和实用性进行了评估。对于异烟肼,与标准方法相比,MGIT显示出12.6%的不一致结果。这些MGIT耐药且小川敏感的菌株具有相对较高的最低抑菌浓度(MIC),范围为0.13至2.0微克/毫升。耐药基因突变的分子检测也是一种快速评估耐药性的有用方法。rpoB突变检测具有高灵敏度和特异性,是可靠的。
用于诊断结核病的核酸扩增试验(NAATs)的灵敏度满足临床需求,即应在一天内识别出具有高传播风险的患者。由于方法和报告之间样本处理和测试样本的差异,比较各种NAATs的性能很困难。考虑到NAATs的局限性(与培养相比灵敏度低,无法区分死菌和活菌),当新技术能够提供额外信息,如药敏性、数量、活力和基因型时,有望取得进一步进展。
鸟分枝杆菌复合群(MAC)在环境中普遍存在,有时在呼吸道中会观察到污染,这使得诊断变得复杂。我们开发了一种以MAC特异性糖肽脂(GPL)核心为抗原的酶免疫测定法用于MAC病的血清学诊断。与MAC定植患者、堪萨斯分枝杆菌病患者、结核病患者和健康受试者相比,MAC肺病患者血清中GPL核心抗体显著增加。该血清学诊断对MAC肺病的诊断有用。
自2001年至今,我们对约1300株培养阳性的临床分离株进行了分子分型,这些分离株构成了大阪东南部部分地区大多数结核菌株。通过Spoligotyping分析,约75%的菌株属于北京株。在IS6110 RFLP拷贝数低于6的菌株中发现了SpolDBIII中未描述的特定Spoligotyping特征。我们将其描述为大阪型。我们还可以证明,通过VNTR可以直接从结核病患者的结核PCR阳性痰中进行分型,并且具有16个位点的VNTR在大阪的结核病分型中很有用。